{"title":"Vascular Pharma完成1600万美元A轮融资并授予Janssen Biotech收购选择权","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1810","DOIUrl":null,"url":null,"abstract":"Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy. The deal follows the successful completion by Vascular Pharma of a US$16 M Series A equity financing, the company’s first institutional round of funding, which it hopes will be sufficient to advance preclinical-stage VPI-2690B through Phase II.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I9.1810\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy. The deal follows the successful completion by Vascular Pharma of a US$16 M Series A equity financing, the company’s first institutional round of funding, which it hopes will be sufficient to advance preclinical-stage VPI-2690B through Phase II.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"21 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I9.1810\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I9.1810","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option
Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy. The deal follows the successful completion by Vascular Pharma of a US$16 M Series A equity financing, the company’s first institutional round of funding, which it hopes will be sufficient to advance preclinical-stage VPI-2690B through Phase II.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
